Fabio Pastorino

Genoa, 16147, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 59 publications

Antitumor Activity of Liposomal Nanoparticles Co-Encapsulating Ceramides and Doxorubicin in In Vitro Nucleolin-Expressing Neuroblastoma Models.

Antitumor Activity of Liposomal Nanoparticles Co-Encapsulating Ceramides and Doxorubicin in In Vitro Nucleolin-Expressing Neuroblastoma Models.

Journal: Cells
Published: April 29, 2026

The gamma delta T/NK cell product GADEKILL as a novel immunotherapeutic tool for neuroblastoma patients: role of B7H6 and BTN2A1 in tumor cell killing.

The gamma delta T/NK cell product GADEKILL as a novel immunotherapeutic tool for neuroblastoma patients: role of B7H6 and BTN2A1 in tumor cell killing.

Journal: Frontiers in immunology
Published: November 27, 2025

L19-Conjugated Gold Nanoparticles for the Specific Targeting of EDB-Containing Fibronectin in Neuroblastoma.

L19-Conjugated Gold Nanoparticles for the Specific Targeting of EDB-Containing Fibronectin in Neuroblastoma.

Journal: Pharmaceutics
Published: November 26, 2025

Patient-derived neuroblastoma models are sensitive to nucleolin-recognizing liposomal drugs.

Patient-derived neuroblastoma models are sensitive to nucleolin-recognizing liposomal drugs.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: September 14, 2025

Dissecting infant leukemia developmental origins with a hemogenic gastruloid model.

Dissecting infant leukemia developmental origins with a hemogenic gastruloid model.

Journal: eLife
Published: September 11, 2025

Ganglioside Profiling Uncovers Distinct Patterns in High-Risk Neuroblastoma.

Ganglioside Profiling Uncovers Distinct Patterns in High-Risk Neuroblastoma.

Journal: International journal of molecular sciences
Published: August 01, 2025

The investigational anti-B7-H3 antibody-drug conjugate vobramitamab duocarmazine exerts anti-tumor activity in vitro and in vivo in pediatric sarcoma preclinical models.

The investigational anti-B7-H3 antibody-drug conjugate vobramitamab duocarmazine exerts anti-tumor activity in vitro and in vivo in pediatric sarcoma preclinical models.

Journal: Cell death & disease
Published: June 23, 2025

From the identification of actionable molecular targets to the generation of faithful neuroblastoma patient-derived preclinical models.

From the identification of actionable molecular targets to the generation of faithful neuroblastoma patient-derived preclinical models.

Journal: Journal of translational medicine
Published: October 25, 2023

Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma.

Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma.

Journal: Journal for immunotherapy of cancer
Published: August 27, 2023

Therapeutic Targeting of ALK in Neuroblastoma: Experience of Italian Precision Medicine in Pediatric Oncology.

Therapeutic Targeting of ALK in Neuroblastoma: Experience of Italian Precision Medicine in Pediatric Oncology.

Journal: Cancers
Published: November 15, 2022

Augmented efficacy of nano-formulated docetaxel plus curcumin in orthotopic models of neuroblastoma.

Augmented efficacy of nano-formulated docetaxel plus curcumin in orthotopic models of neuroblastoma.

Journal: Pharmacological research
Published: August 15, 2022

Italian Precision Medicine in Pediatric Oncology: Moving beyond Actionable Alterations.

Italian Precision Medicine in Pediatric Oncology: Moving beyond Actionable Alterations.

Journal: International journal of molecular sciences
Published: July 21, 2022
Showing 1-12 of 59

Last Updated: 09/26/2026